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Abstract 29 
Understanding how incompletely cleared primary tumors transition from minimal 30 
residual disease (MRD) into treatment resistant, immune-invisible recurrences has major clinical 31 
significance. We show here that this transition is mediated through the subversion of two key 32 
elements of innate immune surveillance.  In the first, the role of TNFD changes from an 33 
antitumor effector against primary tumors into a growth promoter for MRD.  Second, whereas 34 
primary tumors induced a natural killer (NK)-mediated cytokine response characterized by low 35 
IL6 and elevated IFNJ, PD-L1hi MRD cells promoted the secretion of elevated levels of IL6 but 36 
minimal IFNJ, inhibiting both NK cell and T-cell surveillance. Tumor recurrence was promoted 37 
by trauma- or infection-like stimuli  inducing VEGF and TNFDwhich stimulated the growth of 38 
MRD tumors. Finally, therapies which blocked PD1, TNFD or NK cells  delayed or prevented 39 
recurrence.  These data show how innate immune surveillance mechanisms, which control 40 
infection and growth of primary tumors, are exploited by recurrent, competent tumors and 41 
identifies therapeutic targets in patients with MRD known to be at high risk of relapse.  42 
43 
Introduction 44 
Tumor dormancy followed by potentially fatal, aggressive recurrence represents a major 45 
clinical challenge for successful treatment of malignant disease since recurrence occurs at times 46 
that cannot be predicted (1),(2-6). Tumor dormancy is the time following frontline treatment in 47 
which a patient is apparently free of detectable tumor, but after which, local or metastatic 48 
recurrence becomes clinically apparent(2-8). Dormancy results from the balance of tumor-cell 49 
proliferation and death through apoptosis, lack of vascularization, immune surveillance(2-5, 9-50 
13), and cancer-cell dormancy and growth arrest(2-4).  Dormancy is characterized by presence of 51 
residual tumor cells (minimal residual disease [MRD])(14) and can last for decades (2, 5, 15-17).   52 
Recurrences are often phenotypically very different from primary tumors, representing 53 
the end product of in vivo selection against continued sensitivity to frontline treatment(18-28). 54 
Escape from frontline therapy is common, in part, because of the heterogeneity of tumor 55 
populations(29, 30), which include treatment-resistant subpopulations(31). Understanding the 56 
ways in which recurrent tumors differ from primary tumors would allow early initiation of 57 
rational, targeted second-line therapy.  Identifying triggers which convert MRD into actively 58 
proliferating recurrence would allow more timely screening and early intervention to treat 59 
secondary disease(32).   60 
To address these issues, we developed several different preclinical models in which 61 
suboptimal frontline treatment induced complete macroscopic regression, a period of dormancy 62 
or MRD, followed by local recurrence.  Thus, treatment of either subcutaneous B16 melanoma 63 
or TC2 prostate tumors with adoptive T-cell transfer(21, 33-35), systemic virotherapy(36, 37), 64 
VSV-cDNA immunotherapy(38, 39), or ganciclovir (GCV) chemotherapy(40-42)  led to 65 
apparent tumor clearance (no palpable tumor) for >40-150 days.  However, with prolonged 66 
follow-up, a proportion of these animals developed late, aggressive local recurrences, mimicking 67 
the clinical situation in multiple tumor types(43-45).  Recurrence was associated with elevated 68 
expression of several recurrence-specific antigens that were shared across tumor types, such as 69 
YB-1 and Topoisomerase-IiĮ (TOPO-,,Į(44), as well as tumor type-specific recurrence 70 
antigens(45).  71 
Here, we show that the transition from MRD into actively proliferating recurrent tumors 72 
is mediated through the subversion of two key elements of innate immune surveillance of tumors 73 
± UHFRJQLWLRQE\QDWXUDONLOOHU1.FHOOVDQGUHVSRQVHWR71)Į  These data show how the 74 
transition from MRD to active recurrence is triggered in vivo and how recurrences use innate, 75 
antitumor immune effector mechanisms to drive their own expansion and escape from immune 76 
surveillance. Understanding these mechanisms can potentially lead to better treatments that delay 77 
or prevent tumor recurrence.    78 
 79 
Materials and Methods 80 
Mice, cell lines, and viruses 81 
6-8 week old female C57Bl/6 mice were purchased from Jackson Laboratories (Bar 82 
Harbor, Maine). The OT-I mouse strain (on a C57BL/6 [H2-Kb] background) was bred at the 83 
Mayo Clinic  and expresses the transgenic T-FHOOUHFHSWRU9Į9ȕVSHFLILFIRUWKH6,,1)(./84 
peptide of ovalbumin in the context of MHC class I, H-2Kb as previously described(46). Pmel-1 85 
transgenic mice (on a C57BL/6 bacNJURXQGH[SUHVVWKH9Į9ȕ7-cell receptor that 86 
recognizes amino acids 25-33 of gp100 of pmel-17 presented by H2-Db MHC class I 87 
molecules(47). Pmel-1 breeding colonies were purchased from The Jackson Laboratory at 6-8 88 
weeks of age and were subsequently bred at Mayo Clinic under normal housing (not pathogen-89 
free) conditions.    90 
The B16ova cell line was derived from a B16.F1 clone transfected with a pcDNA3.1ova 91 
plasmid(33). B16ova cells were grown in DMEM (HyClone, Logan, UT, USA) containing 10% 92 
FBS (Life Technologies) and G418 (5 mg/mL; Mediatech, Manassas, VA, USA) until challenge.  93 
B16tk cells were derived from a B16.F1 clone transfected with a plasmid expressing the Herpes 94 
Simplex Virus thymidine kinase (HSVtk) gene. Following stable selection in puromycin (1.25 95 
ȝg/mL), these cells were shown to be sensitive to ganciclovir (GCV; cymevene) at 5 µg/ml(40, 96 
41). For experiments where cells were harvested from mice, tumor lines were grown in DMEM 97 
containing 10% FBS and 1% Pen/Strep (Mediatech).   Where appropriate, adherent cells were 98 
confirmed to be B16tk cells by the expression of melanin and by qrtPCR for the HSVtk gene. 99 
Cells were authenticated by morphology, growth characteristics, PCR for  melanoma 100 
specific gene expression (gp100, TYRP-1 and TYRP2) and biologic behavior, tested 101 
mycoplasma-free and frozen.  Cells were cultured less than three months after resuscitation. 102 
Wildtype Reovirus type 3 (Dearing strain) stock titers were measured by plaque assays 103 
on L929 cells (a kind gift from Dr. Kevin Harrington, Institute of Cancer Research, Fulham 104 
Road, London).   Briefly, 6 well plates were seeded with 750,000 L929 cells/well in DEMEM + 105 
10%FBS and incubated overnight.  Cells were washed once with PBS.  1ml of serial dilutions of 106 
the test Reovirus stocks were pipetted into each well, with each dilution run in duplicate.  Cells 107 
were incubated with virus for 3 hours.  Media and virus was aspirated off the cells and 2ml of 108 
1% Noble agar (diluted from a 2% stock with 2x DMEM/10% FBS) at 42oC was added to each 109 
well.  Plates were incubated for 4-5 days until plaques were visible, when wells were stained 110 
with 500µl of 0.02% neutral red for 2 hours and plaques were counted.. For in vivo studies, 111 
reovirus was administered intravenously (i.v.) at 2 x 107 TCID50 (50% tissue culture infective 112 
dose) per injection.  113 
In vivo experiments 114 
C57BL/6J (catalog no. 000664) and B6.129S2-Il6 tm1Kopf/J IL-6 Knockout 115 
(catalog no. 002650) mice were purchased from the Jackson Laboratory.   116 
All in vivo studies were approved by the Mayo IACUC. Mice were challenged 117 
subcutaneously (s.c) with 5 x 105 B16ova, B16tk, RU%PHODQRPDFHOOVLQȝ/3%6118 
(HyClone). Tumors were measured 3 times per week using Bel-Art SP Scienceware Dial-type 119 
calipers, and mice were euthanized with CO2 when tumors reached 1.0 cm diameter. 120 
For suboptimal adoptive T-cell therapy (in which more than 50% of treated mice would 121 
undergo complete macroscopic regression followed by local recurrence), mice were treated i.v. 122 
with PBS or 106 4-day activated OT-I T cells on days 6 and 7 post B16ova injection as 123 
previously described (21, 43).      124 
For GCV chemotherapy experiments, C57BL/6 mice were treated with GCV 125 
intraperitoneally (i.p). at 50 mg/ml on days 6-10 and days 13-17 post s.c. B16tk injection.  126 
For suboptimal, systemic virotherapy experiments, C57BL/6 mice with 5-day established 127 
B16 tumors were treated i.p. with PBS or paclitaxel (PAC) at 10 mg/kg body weight (Mayo 128 
Clinic Pharmacy, Rochester, MN) for 3 days followed by i.v. reovirus (2 x 107 TCID50) or PBS 129 
for 2 days. This cycle was repeated once and was modified from a more effective therapy 130 
previously described(36). 131 
To prevent or delay tumor recurrences, mice were treated i.v. with anti-PD1 (0.25 mg;  132 
catalog no. BE0146; BioXcell, West Lebanon, NH), anti-TNFD (1 µg; catalog no. AF-410-NA; 133 
R&D Systems), anti±asialo GM1 (0.1 mg;  catalog no. CL8955; Cedarlane, Ontario, Canada) or 134 
isotype control rat IgG (catalog no. 012-000-003; Jackson Immuno Research) antibody at times 135 
as described in each experiment. 136 
Establishment of MRD tumor-cell cultures from skin explants   137 
Mice treated with GCV, OT-I T cells, or reovirus that had no palpable tumors following 138 
regression and macroscopic disappearance for >40 days had skin from the sites of B16tk, 139 
B16ova, or B16 injection explanted. Briefly, skin was mechanically and enzymatically 140 
dissociated and ~103-104 cells wereplated in 24-well plates in DMEM containing 10% FBS and 141 
1% Pen/Strep.  24hrs laterwells were washed three times with PBS, and 7 days later inspected 142 
microscopically for actively growing tumor-cell cultures.   143 
Quantitative RT-PCR (qrtPCR) 144 
B16 cells or MRD B16 cells expanded from a site of tumor injection for 72 hrs in TNF-D 145 
in vitro, were cultured for 48 hours in serum-free medium. Cells were then harvested, and RNA 146 
was prepared with the QIAGEN RNeasy Mini Kit. 1 µg total RNA was reverse-transcribed in a 147 
20 µl volume using oligo-(dT) primers and the Transcriptor First Strand cDNA synthesis kit 148 
(catalog no. 04379012001; Roche).  A LightCycler 480 SYBR Green I Master kit was used to 149 
SUHSDUHVDPSOHVDFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV%ULHIO\ 1 ng of cDNA was diluted 150 
(neat [undiluted], 1:10, 1:100, 1:1000) and amplified with gene-specific primers using GAPDH 151 
as a normalization control.  Expression of the murine TOPO-,,ĮJHQHZDVGHWHFWHGXVLQJWKH152 
IRUZDUGƍ-GAGCCAAAAATGTCTTGTATTAG-ƍDQGUHYHUVHƍ-153 
GAGATGTCTGCCCTTAGAAG-ƍSULPHUV([SUHVVLRQRIWKHPXULQH*$3'+JHQHZDV154 
detected using the forward ¶-TCATGACCACAGTCCATGCC-¶DQGUHYHUVH¶-155 
TCAGCTCTGGGATGACCTTG-¶SULPHUV3ULPHUVZHUHGHVLJQHGXVLQJWKH1&%,3ULPHU156 
Blast primer designing tool. 157 
Samples were loaded into a 96-well PCR plate in duplicate and ran on a LightCycler480 158 
instrument (Roche). The threshold cycle (Ct) at which amplification of the target sequence was 159 
detected was used to compare the relative expression of mRNAs in the samples using the 2-ǻǻ&W 160 
method. 161 
Immune-cell activation 162 
Spleens and lymph nodes (LNs) were immediately excised from euthanized C57BL/6 or 163 
OT-I mice and dissociated in vitro to achieve single-cell suspensions. Red blood cells were lysed 164 
with ACK lysis buffer (Sigma-Aldrich, St. Louis, MO) for 2 minutes. Cells were resuspended at 165 
1 x 106 FHOOVP/LQ,VFRYH¶V0RGLILHG'XOEHFFR¶V0HGLXP,MDM; Gibco, Grand Island, NY) 166 
supplemented with 5% FBS, 1% Pen-Strep, ȝ0-BME. Cells were cocultured with target 167 
B16 or B16MRD cellsas described in the text. Cell-free supernatants were then collected 72 168 
hours later  and tested for ,)1Ȗ0RXVH,)1Ȗ(/,SA Kit; OptEIA, BD Biosciences, San Diego, 169 
&$DQG71)Į%'%LRVFLHQFHV6DQ-RVH&$production by ELISA as directed in the 170 
PDQXIDFWXUHU¶VLQVWUXFWLRQV.  171 
NK cells were prepared from spleens of naïve C57BL/6 mice using the NK Cell Isolation 172 
Kit II (Miltenyi, Auburn, CA) as described LQWKH³1.FHOOLVRODWLRQ´VHFWLRQ and cocultured with 173 
B16 or B16MRD target tumor cells at E:T ratios of 20:1. 72 hours later, supernatants were 174 
assayed for IFNJ or IL6 by ELISA. 175 
Cytokines and antibodies 176 
Cytokines and cytokine neutralizing antibodies were added to cultures upon plating of the 177 
cells and  used at the following concentrations in vitro:  VEGF165 (12 ng/mL; catalog no. CYF-178 
336; Prospec-Bio), TNFD (100 ng/mL; catalog no. 31501A; Peprotech), IL6 (100 pg/mL; catalog 179 
no. 216-16; PeproTech), anti-TNFD (0.4µg/ml; catalog no. AF410NA; R&D Systems), universal 180 
IFND (100U; catalog no. 11200-2; R&D Systems), anti-IL6 (1 µg/ml; catalog no. MP5-20F3; 181 
BioLegend, San Diego), LPS (25 ng/ml; catalog no. L4524; Sigma), CpG (25 ng/ml; Mayo 182 
Clinic Oligonucleotide Core facility). 183 
Immune cell depletion 184 
 Splenocyte/LN cultures were depleted of different immune cell types (asialo GM-1+ 185 
(NKs), CD4+, CD8+, CD11c+, or CD11b+ cells) by magnetic bead depletion (catalog no. 130-186 
052-501 (NK); 130-104-454 (CD4); 130-104-075 (CD8); 130-108-338 (CD11c) and 130-049-187 
&'E0LOWHQ\L%LRWHFK&$86$DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV 188 
In addition, splenocyte/LN cultures were depleted using the RB6-8C5 (8µg/ml) (R&D Systems, 189 
catalog no. MAB1037) and 1A8 (1µg/ml) (BioLegend, catalog no. 127601) antibodies.  While 190 
1A8 recognizes only Ly-6G (Gr1), clone RB6-8C5 recognizes both Ly-6G and Ly-6C.  Ly6G is 191 
differentially expressed in the myeloid lineage on monocytes, macrophages, granulocytes, and 192 
peripheral neutrophils. RB6-8C5 is typically used for phenotypic analysis of monocytes, 193 
macrophages and granulocytes whilst 1A8 is typically used to characterize neutrophils.  194 
NK cell isolation and flow cytometry 195 
Mouse NK cells were isolated from single cell suspensions of the dissociated spleens of 196 
6-ZHHNROG&%/PLFHXVLQJWKH1.&HOO,VRODWLRQ.LW,,DFFRUGLQJWRWKHPDQXIDFWXUHU¶V197 
instructions (Miltenyi Biotec, Auburn, CA). In this protocol, T cells, dendritic cells, B cells, 198 
granulocytes, macrophages, and erythroid cells are indirectly magnetically labeled with a 199 
cocktail of biotin-conjugated antibodies and anti-biotin microbeads for 15 minutes. After 200 
depleting magnetically labeled cells, isolation and enrichment of unlabeled NK cells was 201 
confirmed by flow cytometry. Isolated NK cells were stained with CD3-FITC (catalog no. 202 
100306; Biolegend, San Diego, CA), NK1.1-PE (catalog no. 108708; Biolegend), PD1-Pe/Cy7 203 
(catalog no. 109109; Biolegend), PD-L1-APC (catalog no. 124311; Biolegend)  to distinguish 204 
enriched NK cells from CD3+ cells.  %ORRGZDVWDNHQHLWKHUVHULDOO\LQDaȝ/VXEPDQGLEXODU205 
vein bleed or from cardiac puncture at the time of sacrifice. Blood was collected in heparinized 206 
tubes, washed twice with ACK lysis buffer, and resuspended in PBS for staining.  207 
Flow cytometry analysis was carried out by the Mayo Microscopy and Cell Analysis core 208 
and data were analyzed using FlowJo software (TreeStar, USA). Enriched NK cells were 209 
identified by gating on NK1.1hi CD49bhi CD3Hlo cells.    210 
In vitro cytokine secretion and flow cytometry 211 
B16 or B16MRD tumor cells cocultured with isolated NK cells were seeded in DMEM  212 
containing 10% FBS and 1% Pen/Strep containing anti-PD1 (catalog no. BE0146; Bio-X-cell, 213 
West Lebanon, NH),  anti-PD-L1 (catalog  no. BE0101; Bio-X-cell), anti-CTLA4 (100 ng/mL; 214 
catalog no. BE0164; Bio X Cell), or isotype control (Chrome Pure anti-Rabbit IgG; catalog no. 215 
011-000-003; Jackson Laboratories, Farmington, CT). 72 hours post-incubation, supernatants 216 
were harvested and analyzed for cytokine secretion using ELISAs for ,)1Ȗ and 7)1Į.  Tumor 217 
cells were stained for CD45-PerCP (BD Bioscience San Diego,CA) and PD-L1-APC (Biolegend, 218 
San Diego,CA). Flow cytometry analysis was performed as discussed. 219 
Phase contrast microscopy 220 
Pictures of B16 or B16MRD cell cultures, under the conditions described in the text, 221 
were acquired using an Olympus-IX70 microscope (UplanF1 4x/0.13PhL), a SPOT Insight-1810 222 
digital camera and SPOT Software v4.6. 223 
Histopathology 224 
Skin at the site of initial tumor cell injection or tumors was harvested, fixed in 10% 225 
formalin, paraffin-embedded, and sectioned. Two independent pathologists, blinded to the 226 
experimental design, examined H&E sections.for the presence of B16 melanoma cells and any 227 
immune infiltrate. 228 
Statistics 229 
In vivo experimental data were analyzed using GraphPad Prism 4 software (GraphPad 230 
Software, La Jolla, CA, USA). Survival data from the animal studies were analyzed using the 231 
log-rank test and the Mann-Whitney U test, and data were assessed using Kaplan-Meier plots. 232 
One-way ANOVA and two-way ANOVAs were applied for in vitro assays as appropriate. 233 
Statistical significance was determined at the level of p < 0.05. 234 
 235 
Results  236 
Model of minimal residual disease (MRD)  237 
We have previously shown that established subcutaneous B16 tumors can be treated with 238 
either prodrug chemotherapy, oncolytic viro-immunotherapy, or adoptive T-cell therapy(21, 34, 239 
36, 43-45). Irrespective of the frontline treatment, histology at the site of initial tumor injection 240 
after tumor regression often showed residual melanoma cells in mice scored as tumor-free (Fig. 241 
1A).   242 
In one experiment, 6/10 mice cleared of B16tk tumors by treatment with ganciclovir 243 
(using a regimen in which 100% of tumors regressed macroscopically followed by ~50-80% of 244 
the mice undergoing later local recurrence)(43) had histological evidence of MRD at 80d post 245 
tumor seeding.  Although parental B16tk cells grow rapidly in tissue culture, no viable B16tk 246 
cells were recovered from separate skin explants 75d following tumor seeding from 15 mice 247 
which had undergone complete macroscopic regressions following ganciclovir (Fig. 1B and H). 248 
The very low frequency of regrowth of B16 cultures from skin explants was reproducible from 249 
mice in which primary B16tk or B16ova tumors were rendered nonpalpable by oncolytic 250 
virotherapy with either reovirus(36),  adoptive T-cell therapy with Pmel(34), or OT-I T cells(21) 251 
(see Table 1 for cumulative summary). 252 
When C57BL/6 splenocytes from tumor-naive mice were cocultured with skin explants 253 
containing MRD B16 cells, no tumor cells were recovered after in vitro culture (Fig. 1C and H).  254 
However, when splenocyte and LN cells from mice which had previously cleared B16 tumors 255 
were cocultured with skin explants, actively proliferating B16 cultures could be recovered in 256 
vitro (Fig. 1D and H).  These data suggest that splenocyte and LN cells from mice previously 257 
vaccinated against primary tumor cells, secret a factor which promotes growth of MRD B16 258 
cells.  In this respect, systemic VEGF can prematurely induce early recurrence of B16 MRD 259 
following frontline therapy that cleared the tumors(43).  Although in vitro treatment of MRD 260 
B16 explants with VEGF did not support outgrowth of B16 cells (Fig. 1E and H), coculture of 261 
splenocytes and LNs from control nontumor-bearing mice with VEGF supported outgrowth at 262 
low frequencies (Fig. 1F and H).  However, coculture of splenocytes and LNs from mice that 263 
cleared B16 primary tumors with VEGF consistently supported outgrowth of MRD B16 cells 264 
with high efficiency (Fig. 1G). 265 
TNF supports outgrowth of MRD   266 
VEGF-treated splenocyte and LN cells from mice that cleared B16 tumors showed rapid 267 
upregulation of TNFD, derived principally from CD11b+ cells (Fig. 2A).  Depletion of CD4+ T 268 
cells enhanced TNFD production from VEGF-treated splenocyte and LN cells (Fig. 2A).  269 
Outgrowth of MRD B16 cells from skin explants following different frontline therapies was 270 
actively promoted by TNFD(Fig. 2B and F) but not by IL6 (Fig. 2C and F) or other cytokines 271 
such as IFNJ (Fig. 2B-F).  Antibody-mediated blockade of TNFD significantly inhibited the 272 
ability of splenocyte and LN cells from mice that cleared B16 tumors to support outgrowth of 273 
MRD B16 cells (Fig. 2D-F).  In contrast to the growth-promoting effects of TNFD on MRD B16 274 
cells, culture of parental B16 cells with TNFD significantly inhibited growth (Fig. 2G).  275 
Consistent with Fig. 2A, monocytes and macrophages  were the principal source of the growth-276 
promoting TNFD in VEGF-treated splenocyte and LN cells from mice that cleared B16 tumors 277 
(Fig. 2G).  Similarly, outgrowth of MRD TC2 murine prostate cells following frontline viro-278 
immunotherapy was also actively promoted by TNFD, whereas TNFD was highly cytotoxic to 279 
the parental tumor cells (Fig. 2I).  Therefore, in two different cell types, TNFD changes from an 280 
antitumor effector against primary tumors into a growth promoter for MRD.  B16 MRD cultures 281 
maintained in TNFD for up to six weeks retained their dependence upon the cytokine for 282 
continued in vitro proliferation.  Withdrawal of TNFD did not induce cell death but prevented 283 
continued proliferation.  Finally, we did not observe reversion to a phenotype in which TNFD 284 
was growth inhibitory within a six-week period.   285 
We did not observe any reduction in the ability of cultures to support outgrowth of MRD 286 
cells when depleted of neutrophils, CD4 cells, or NK cells, whereas depletion of Ly6G+ cells 287 
(completely) and CD8+ T cells (partially) inhibited outgrowth (Fig. 2H).   Therefore, taken 288 
together with the dependence of TNFD production on CD11b+ cells, our data suggest that 289 
CD11b+ monocytes and macrophages are the principal cell type responsible for the TNFD-290 
mediated outgrowth of B16 MRD recurrences, although CD8+ T cells also play a role.  291 
TNFDexpanded MRD acquires a recurrence competent phenotype   292 
The recurrence competent phenotype (RCP) of B16 cells emerging from a state of MRD 293 
is associated with transient high expression of Topoisomerase IID (TOPO-,,Įand YB-1(44) and 294 
acquired insensitivity to innate immune surveillance(43). Therefore, we investigated whether the 295 
B16 MRD cultures, which we could induce with TNFD resembled this same phenotype to 296 
validate their identity as recurrent tumors.  MRD B16 cells expanded in vitro with TNFD 297 
overexpressed both Topo-IID and YB-1 compared to parental B16, consistent with their 298 
acquisition of the RCP (Fig. 3A).  Coculture of skin explants with TNFD or splenocyte and LN 299 
cultures induced outgrowth of MRD B16 cells (Fig. 3B and D), which were sensitive to the 300 
Topo-IID-targeting drug doxorubicin (Fig. 3C and E).  MRD B16 cells expanded in TNFD were 301 
also insensitive to the antiviral protective effects of IFND upon infection with reovirus and 302 
supported more vigorous replication of reovirus than parental B16 cells (Fig. 3F), consistent with 303 
acquisition of the RCP(43).  In contrast, IFND protected parental B16 cells from virus 304 
replication. 305 
MRD cells lose sensitivity to NK immune surveillance  306 
The recurrence competent phenotype is also associated with an acquisition of an 307 
insensitivity to innate immune effectors(44).  Therefore, we next investigated whether NK cells, 308 
a major effector of innate immune surveillance of tumors, differentially recognized primary B16 309 
compared to their B16 MRD derivatives.  For the following experiments, a homogenous 310 
population of untouched splenic NK1.1hi CD49bhi CD3HLo NK cells were isolated from spleens 311 
of C57BL/6 mice. Although purified NK cells secreted significant amounts of IFNJ upon 312 
coculture with parental B16 cells, TNFD-expanded MRD B16 cultures did not stimulate IFNJ 313 
from NK cells (Fig. 4A).  Consistent with reports of a spike in serum IL6 just prior to the 314 
emergence of tumor recurrences(43), cocultures of purified NK cells from wildtype mice, but not 315 
from IL6 knockout mice, produced IL6 in response to MRD B16, but not parental B16, cells 316 
(Fig. 4B). Intracellular staining confirmed that an NK1.1+ cell population within wildtype 317 
splenocytes differentially recognized parental B16 and B16 MRD cells through IL6 expression 318 
(Fig. 4C).  IL6 was detected in excised small recurrent tumors but not in small primary tumors, 319 
whereas TNFD could not be detected in recurrent tumors but was present at very low amounts in 320 
some primary tumors (Fig. 4D).  Although subcutaneous injection of 103 MRD B16 cells 321 
generated tumors in 100% of mice, a similar dose of parental B16 cells did not generate tumors 322 
in any of the 5 animals (Figs. 4E and F).  However, when mice were depleted of NK cells prior 323 
to tumor challenge,  103 parental B16 cells became tumorigenic in 100% of the animals (Fig. 324 
4E).  NK cell depletion had no effect on the already high tumorigenicity of the same dose of 325 
MRD B16 cells (Fig. 4F). Therefore, MRD B16 cells expanded in TNFD were significantly more 326 
tumorigenic than parental B16 cells,  in part, because they were insensitive to NK cell 327 
recognition. 328 
Differential recognition of primary and MRD cells by NK cells  329 
Both MRD B16 cells expanded in TNFD and a freshly resected tumor upregulated the T-330 
cell checkpoint inhibitory molecule PD-L1(48, 49),  whereas PD-L1 expression was low on 331 
parental B16 cells and lower on a freshly resected primary tumor, whether or not it was treated 332 
with TNFD (Fig. 5A).  333 
Although purified NK cells did not secrete IFNJ in response to TNFD-expanded MRD B16 cells 334 
or to early recurrent B16 tumor explants (Fig. 4A), they did SURGXFH,)1ȖLQWKHSUHVHQFHRI335 
parental B16 cells and primary B16 tumors (Fig. 5B).  Blockade of PD-L1 on MRD B16 cells 336 
inceased NK cell-mediated IFNJ secretion and also significantly enhanced NK cell response to 337 
parental B16 cells (Fig. 5B).  Conversely, NK cell-mediated IL6 secretion in response to MRD 338 
B16 cells was significantly decreased by blockade of PD-L1 (Fig. 5C). However,PD-L1 339 
blockade did not alter the inability of parental B16 cells to stimulate IL6 secretion from purified 340 
NK cells (Fig. 5C). 341 
NK cell-mediated IL6 inhibits T-cell recognition of MRD  342 
MRD B16ova cells recovered from skin explants of B16ova primary tumors rendered to a 343 
state of MRD by adoptive OT-I T-cell therapy(21) still retained high expression of the target 344 
OVA antigen, suggesting that antigen loss is a later event in the progression to recurrent tumor 345 
growth (Fig. 5D). As expected, OT-I T cells secreted IFNJ upon coculture with B16ova cells in 346 
vitro and  was augmented by coculture with NK cells from either wildtype or IL6 KO mice (Fig. 347 
5E). Anti-IL6 had no effect on OT-I recognition of parental B16ova cells irrespective of the 348 
source of the NK cells (Fig. 5E). Although TNFD-expanded MRD B16ova cells still expressed 349 
OVA (Fig. 5D), they elicited significantly lower IFNJ from OT-I and NK cells alone (Fig. 5F). 350 
Coculture of OT-I T cells with wildtype, but not with IL6 KO, NK cells abolished IFNJ 351 
production in response to MRD B16ova cells (Fig. 5F and G) and was reversed by IL6 blockade 352 
(Fig. 5F).  After 7d of coculture with OT-I and NK cells, surviving parental B16ova cells had 353 
lost OVA expression, irrespective of the IL6 presence (Fig. 5H).  However, only in the presence 354 
of IL6 blockade did  MRD B16ova cells rapidly lose OVA expression (Fig.5G).  These data 355 
suggest that NK-mediated IL6 expression in response to TNFD-expanded MRD cells can inhibit 356 
T-cell recognition of its cognate antigen expressed by tumor targets and, thereby, slow the 357 
evolution of antigen loss variants. 358 
Phenotypic analysis of the lymphoid cells from tumor naive mice compared with those 359 
from mice cleared of tumor showed minimal differences in subsets of CD4+ T cells (Fig. 6A-D). 360 
In addition to a non-significant trend towards an increase in circulating CD8+ effector cells 361 
(CD44Hi CD62LLo) in mice cleared of tumor (Fig.  6E), effector cells expressing both inhibitory 362 
receptors PD1 and TIM-3 were also consistently higher compared to tumor naïve mice (Fig. 6F).  363 
These data suggest that mice with tumors that have been treated successfully through 364 
immunotherapeutic frontline treatments contain populations of antitumor effector cells that may 365 
be functionally impaired to some degree due to elevated expression of checkpoint inhibitor 366 
molecules. 367 
Inhibition of tumor recurrence   368 
Based on these data, several molecules and cells ± VEGF, CD11b+ cells, TNFD, PD-L1, 369 
NK cells ± would be predicted to play an important role in mediating the successful transition 370 
from MRD to actively expanding recurrence. After primary B16tk tumors had regressed 371 
following chemotherapy with GCV(43), about half of the mice routinely developed recurrences 372 
between 40-80 days following complete macroscopic regression of the primary tumor (Fig. 7A). 373 
However, long-term treatment with antibody-mediated blockade of either PD1 or TNFD 374 
effectively slowed or prevented recurrence (Fig. 7A).  The depletion of NK cells also prevented 375 
recurrence of B16tk tumors (Fig. 7A), consistent with their secretion of T-cell inhibitory IL6. 376 
Our data would also predict that systemic triggers that induce VEGF(43) and/or TNFD 377 
from host CD11b+ cells would accelerate tumor recurrence. In vitro, LPS stimulation of 378 
splenocyte and LN cultures induced high TNFD (Fig. 7B) and also supported the outgrowth of 379 
5/8 MRD B16 skin explants, an effect which was eradicated by blockade of TNFD (Fig. 7C).  380 
Therefore, we tested systemic treatment with TNFD-inducing LPS as a mimic of a trauma or 381 
infection that may induce recurrence.  Primary tumors that macroscopically regressed into a state 382 
of MRD were prematurely induced to recur in 100% of mice following treatment with LPS, 383 
consistent with an LPS/TNFD induced mechanism of induction of recurrence from a state of 384 
MRD (Fig. 7D).  Under these conditions, depletion of NK cells significantly delayed recurrence 385 
but did not prevent it (Fig. 7D), unlike in the model of spontaneous recurrence (Fig. 7A).   386 
Prolonged treatment with antibody-mediated blockade of either PD1 or TNFD successfully 387 
prevented long-term recurrence, even when mice were treated with LPS (in 100% of mice in the 388 
experiment of Fig. 7D, and in 7/8 mice in a second experiment). 389 
 390 
Discussion  391 
We have developed models in which several different frontline therapies reduced 392 
established primary tumors to a state of MRD with no remaining palpable tumor(43-45).  393 
However, in a proportion of mice in this study, frontline therapy was insufficient to eradicate all 394 
tumor cells, leaving histologically detectable disease. Explants of skin at the site of tumor cell 395 
injection following regression rarely yielded actively proliferating B16 cells, even though >50% 396 
of samples contained residual tumor cells.  The frequency with which cultures of MRD cells 397 
were recovered following explant was significantly increased by coculture with splenocytes and 398 
LN cells from mice previously treated for tumors, and this effect was enhanced by VEGF , which 399 
induced TNFD from CD11b+ cells.  Taken together, we believe that CD11b+ monocytes and 400 
macrophages are the principal cell type responsible for the VEGF-mediated induction of TNFD 401 
and for the TNFD-mediated outgrowth of B16 MRD recurrences. Although we showed TNFD 402 
was highly cytotoxic to parental B16 cells and primary tumor explants, TNFD supported 403 
expansion of MRD cells from skin explants at high frequency, irrespective of the primary 404 
treatment.  As shown previously, splenocytes from mice with cleared B16 tumors after GCV 405 
treatment killed significantly higher numbers of target B16 cells in vitro than did splenocytes 406 
from control, tumor naïve mice, confirming the generation of an effective antitumor T-cell 407 
response(42).  In contrast, here we show no significant difference between killing of B16MRD 408 
cells expanded for 120hrs in TNFD in vitro by splenocytes from mice that cleared a B16 tumor 409 
compared to splenocytes from control, tumor naive mice. We are currently investigating the 410 
molecular mechanisms by which B16MRD cells effectively evade the antitumor T-cell responses 411 
induced by frontline treatment (such as GCV, T-cell therapy, or oncolytic virotherapy). 412 
TNFD-mediated expansion of MRD B16 cells induced the recurrence competent 413 
phenotype (RCP)(43, 44), shown by de novo expression of recurrence-associated genes (YB-1 414 
and Topoisomerase IID)(44).  Re-activation of metastatic cells lying latent in the lungs has been 415 
associated with expression of the Zeb1 transcription factor, which mediates the epithelial-to-416 
mesenchymal transition (EMT)(50). NK cells are major innate effectors of immune surveillance 417 
of tumors and responded  differently to recurrent competent MRD B16 cells compared to 418 
primary B16 cells.  We show NK cells were activated by parental B16 cells to secrete IFNJ and 419 
were major effectors of in vivo tumor clearance.  In contrast, TNFD-expanded MRD B16 cells 420 
induced NK cells to secrete IL6 instead of IFNJ, which was not seen for parental B16 cells, 421 
effects mediated, in part, through PD-L1. IL6 produced by NK cells in response to TNFD-422 
expanded MRD B16ova cells also inhibited OT-I T-cell recognition of OVA+ tumor targets.  423 
TNFD-expanded MRD cells still retained expression OVA, despite using frontline OVA-targeted 424 
T-cell therapy. Only upon prolonged coculture of OVA+  MRD cells with OT-I+ NK cells with 425 
IL6 blockade was significant antigen loss observed, consistent with the long-term, but not early, 426 
loss of OVA antigen expression from B16ova recurrences following OT-I adoptive T-cell 427 
therapy(43) (21). Therefore, antigen loss in MRD cells is not an essential prerequisite for the 428 
emergence of tumor recurrences (21) and may occur through powerful selective pressure on very 429 
early antigen positive recurrent tumors as they expand in vivo in the presence of ongoing antigen 430 
targeted T-cell pressure. 431 
Our data here are consistent with a model in which the transition from quiescent MRD to 432 
actively expanding recurrence is promoted by the acquisition of a phenotype in which TNFD 433 
changes from being a cytotoxic growth inhibitor (against primary tumors), to promoting the 434 
survival and growth of one, or a few, MRD cells.  It is not clear whether these TNFD responsive 435 
clones exist within the primary tumor population, perhaps as recurrence competent stem 436 
cells(31), or whether this RCP is acquired by ongoing mutation during the response to frontline 437 
therapy(9, 14, 29, 30).  Since established primary B16 and B16 MRD tumors both have low 438 
intratumoral NK infiltration, we hypothesize that the differential recognition of B16 or B16 439 
MRD cells by NK cells occurs at very early stages of tumor development. Therefore, it may be 440 
that different subsets of NK cells mediate the differential recognition of primary B16 (rejection) 441 
or B16 MRD (growth stimulation).  However, in our experiments here a homogenous population 442 
of untouched splenic NK1.1hi CD49bhi CD3Hlo NK cells differentially recognized parental B16 443 
and B16 MRD cells, suggesting that the basis for these different NK responses are, in large part, 444 
due to tumor-cell intrinsic properties.  These recurrence competent MRD cells are insensitive to 445 
both innate and adaptive immune surveillance mechanisms, in part, through expression of PD-446 
L1. With respect to escape from adaptive immune surveillance, we show both that the MRD cells 447 
express high levels of PD-L1 and that the fraction of effector cells expressing both inhibitory 448 
receptors PD1 and TIM-3 was consistently higher in tumor experienced mice than tumor naïve 449 
mice.  Integral to both innate and adaptive immune evasion, TNFD-expanded MRD tumor cells 450 
induced an anti-inflammatory profile of IL6hi and IFNJlo expression from NK cells, the opposite 451 
of the profile of NK recognition (IL6lo IFNJhi) induced by parental primary tumor cells.  This 452 
altered role of NK cells as prorecurrence effectors, as opposed to antitumor immune effectors, 453 
was due to impaired killing of MRD cells and recurrent tumor cells plus the secretion of IL6.  454 
This NK-derived IL6, in turn, inhibited T-cell responses against recurrent tumors, even when 455 
they continued to express T cell±specific antigens. 456 
This model showed several molecules and cells ± VEGF, CD11b+ cells, TNFD, PD1/PD-457 
L1, NK cells ±can be targeted for therapeutic intervention to delay recurrence.  In our model of 458 
spontaneous recurrence, depletion of NK cells or antibody-mediated blockade of either TNFD or 459 
PD1, significantly inhibited tumor recurrence following frontline GCV.  Our data suggests that a 460 
systemic trigger ± such as VEGF-induced by trauma or infection ± promotes TNFD release from 461 
host CD11b+ cells leading to growth stimulation of MRD cells.  Consistent with this, LPS both 462 
induced TNFD from splenocytes and LN cells and mimicked TNFD in the generation of 463 
expanding MRD cultures from skin explants. Recurrence could be induced prematurely by LPS, 464 
as a mimic of a systemic infection/trauma, consistent with a report in which LPS treatment re-465 
activated intravenously injected disseminated tumor cells pre-selected for properties of 466 
latency(50).  These results suggest that patients in a state of MRD may be at significantly 467 
increased risk of recurrence following infections and/or trauma, which induce the release of 468 
systemic VEGF and/or TNFD.  However, blockade of PD1 or TNFD following this trauma-like 469 
event prevented tumor recurrence.  We are currently investigating when, and for how long, these 470 
potentially expensive recurrence blocking therapies will be required to be administered in 471 
patients.  This is especially relevant for those patients in whom MRD may be present over 472 
several years before recurrence is triggered.  Transcriptome analysis of MRD and early 473 
recurrences, compared to parental tumor cells, is underway in both mouse models (B16 and TC2) 474 
as well as in patient samples where matched pairs of primary and treatment failed recurrence 475 
tumors are available.  These studies will identify the signaling pathways which differ between 476 
the cell types to account for their differential responses to TNFD signaling and IFNJ and IL6 477 
production by NK cells.  Future studies will focus on identifying which cells become recurrent 478 
tumors, the mutational and selective processes involved in the transition, identification of the 479 
biological triggers for recurrence(1, 32), and the time over which recurrence inhibiting therapies 480 
must be administered.   481 
In summary, we show here that the transition from MRD to recurrence involves the 482 
subversion of normal innate immune surveillance mechanisms.  In particular, TNFD produced in 483 
response to pathological stimuli becomes a prorecurrence, as opposed to antitumor, growth 484 
factor.  Simultaneously, NK cells, which normally restrict primary tumor growth, fail to kill 485 
expanding recurrent tumor cells and produce IL6 that helps to suppress adaptive T-cell 486 
responses, even with continued expression of T cell±targetable antigens.  Finally, our data show 487 
that therapies aimed at blocking certain key molecules (PD1, TNFD) and cell types (NK cells) 488 
may be valuable in preventing this transition from occurring in patients.  489 
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  629 
Figure Legends 630 
Figure 1.  Model of minimal residual disease.  A-G, Histological sections; A, Skin at the site 631 
of B16 cell injection from a C57BL/6 mouse treated with Pmel adoptive T-cell therapy with 632 
VSV-gp100 viro-immunotherapy(34). B-D, Skin explants from the site of B16tk cell injection 633 
from mice treated with GCV (no palpable tumor after regression) were B, left untreated;  C, 634 
cocultured with 105 splenocytes and LN cells from normal C57BL/6 mice; or D, cocultured with 635 
105 splenocytes and LN cells from C57BL/6 mice cleared of B16tk tumors after GCV treatment.  636 
7 days later, wells were inspected for actively growing tumor cells. Images are representative of 637 
nine independent experiments with explants from different primary treatments. E-H,  Skin from 638 
the sites of cleared B16tk tumors were explanted and treated as in B and were cocultured with E, 639 
VEGF (12ng/ml);  F, VEGF and 105 splenocytes and LN cells from normal C57BL/6 mice; or G, 640 
VEGF and 105 splenocytes and LN cells from C57BL/6 mice cleared of B16tk tumors after GCV 641 
treatment. 3 separate explants per treatment were counted. H,  Quantitation of B-G.   642 
Figure 2.  MRD cells use TNFD as a growth factor.  A,  105 splenocytes and LN cells from 643 
C57BL/6 mice cleared of B16tk tumors (after GCV) were depleted of asialo GM-1+ (NKs), 644 
CD4+, CD8+, CD11c+, or CD11b+ cells by magnetic bead depletion and plated in the presence or 645 
absence of VEGF165 (12ng/ml) in triplicate.  Cell supernatants were assayed for TNFD by ELISA 646 
after 48 hours.  Mean and standard deviation of triplicate wells are shown.  Representative of two 647 
separate experiments.  *** p<0.0001 (t Test).  B and C, Skin from the B16tk cell injection site 648 
from mice treated with GCV (no palpable tumor after regression) was treated with B, TNFD 649 
(100ng/ml) or C, IL6 (100pg/ml). 7 days later, wells were inspected for actively growing tumor 650 
cell cultures.  Images are representative of 15 skin explants over five different experiments.  D 651 
and E, Skin explants from the site of B16tk cell injection of mice treated with GCV (no palpable 652 
tumor)cocultured with 105 splenocytes and LN cells from C57BL/6 mice cleared of B16tk 653 
tumors after GCV treatment (D) alone; or (E) in the presence of anti-TNFD (0.4µg/ml) 7 days 654 
later, wells were inspected for actively growing tumor cells.  Images are representative of 5 655 
separate explants.  (F)  Quantitation of B-E.  3 separate explants per treatment were counted.  G,  656 
104 parental B16 cells, explanted B16 cells  from a PBS-treated mouse, or cells from two MRD 657 
B16 cultures (expanded in vitro in TNFD for 72 hrs) were plated in triplicate and grown in the 658 
presence or absence of TNFD for 4 days.  Surviving cells were counted.  Mean and standard 659 
deviation of triplicates are shown.  Representative of three experiments. *p<0.01; ** p<0.001 660 
(ANOVA).  H,  Splenocytes and LN cells from C57BL/6 mice cleared of B16tk tumors after 661 
GCV treatment were treated with no antibody or with depleting antibodies specific for CD8, 662 
CD4, asialo GM-1(NK cells), monocytes and macrophages, or neutrophils. Skin samples from 663 
regressed tumor sites were cocultured with 105 depleted or non-depleted splenocytes and LN 664 
cultures in the presence of VEGF165 (12ng/ml).  7 days later, wells were inspected for actively 665 
growing tumor cell cultures.  The percentage of cultures positive for active MRD growth (wells 666 
contained >104 adherent B16 cells) is shown.  I, 104 explanted TC2 tumor cells from a PBS-667 
treated mouse or cells from two MRD TC2 cultures (expanded in vitro in TNFD for 72 hrs) were 668 
plated in triplicate and grown in the presence or absence of TNFD for 4 days.  Surviving cells 669 
were counted.  Mean and standard deviation of triplicates are shown. *p<0.01; ** p<0.001 670 
(ANOVA). 671 
 672 
Figure 3.  TNFD-expanded MRD cells acquire the recurrence competent phenotype.  A, 5 x 673 
104 B16 cells or MRD B16 cells (expanded from a site of tumor injection for 72 hrs in TNFD) 674 
were plated in triplicate.  24 hours later, cDNA was analyzed by qrtPCR for expression of YB-1 675 
or TOPO-IID.  Relative quantities of mRNA were determined.  *p<0.05; Mean of the triplicate is 676 
shown.  Representative of two separate experiments with two different B16 MRD recurrences. 677 
B-E, Skin explant from theB16tk cell injection site from mice treated with GCV was plated with 678 
B, TNFD (100ng/ml); C, TNFD  plus doxorubicin (0.1mg/ml); or cocultured with VEGF and 105 679 
splenocytes and LN cells from C57BL/6 mice cleared of B16tk tumors after GCV treatment D, 680 
without; or E, with doxorubicin. 7 days later, wells were inspected for actively growing tumor 681 
cells.  Representative of three  B16 MRD explants.  F, 103 B16 cells or MRD B16 cells 682 
(expanded from a site of tumor injection for 72 hrs in TNFD) were plated in triplicate.  Cells 683 
were infected with reovirus (MOI 1.0) in the presence or absence of IFND (100U) for 48 hours 684 
and titers of reovirus determined.  Mean and standard deviation of triplicates are shown, ** 685 
p<0.001 (ANOVA). 686 
 687 
Figure 4.  Parental and MRD cells are differentially recognized by NK cells.  B16 or MRD 688 
B16 cells (105 per well) were cocultured in triplicate with purified NK cells from either wildtype 689 
C57BL/6 (IL6+) or IL6 KO mice at an effector:target ratio of 20:1.  72 hours later, supernatants 690 
were assayed for A, IFNJ or B, IL6 by ELISA.  Mean and standard deviation of triplicates are 691 
shown, *p<0.05 ** p<0.001 (ANOVA).  Representative of three separate experiments.  C,  692 
Splenocytes and LN cells from wildtype C57BL/6 mice were plated with B16 or B16 MRD #2 693 
cells and grown for 72hrs in TNFD at an effector:target ratio of 50:1.  72 hours later, cells were 694 
harvested and analyzed for expression of NK1.1 and IL6. D,  Three small primary B16ova 695 
tumors (<0.3cm diameter, Pri#1-3) from PBS-treated C57BL/6 mice or three small recurrent 696 
B16ova tumors from mice were excised, dissociated, and plated in 24-well plates overnight 697 
thensupernatants were assayed for IL6 and TNFD by ELISA.  Mean and standard deviation of 698 
triplicates are shown; *** p<0.0001, for IL6 between primary and recurrent tumors (t test).  E 699 
and F, C57BL/6 mice (n= 5 mice/group) were challenged subcutaneously with E, parental 700 
B16ova cells; or F, B16ova MRD cells (expanded from a regressed B16ova tumor site for 72 hrs 701 
in TNFD at doses of 103 or 104 cells per injection.   Included in E and F is a  group of mice 702 
depleted of NK cells using anti-asialo GM-1 and challenged with 103 B16 or B16 MRD cells.  703 
Representative of two separate experiments.  Survival analysis was conducted using log-rank 704 
tests.  The threshold for significance was determine by using the Bonferroni correction for 705 
multiple comparisons. 706 
Figure 5. PD-L1 expression on MRD inhibits immune surveillance through IL6.  A,  707 
Expression of PD-L1 was analyzed by flow cytometry on parental B16 cells in culture.  Cells 708 
from a small (~0.3cm diameter) B16tk tumor explanted from a PBS-treated mouse were cultured 709 
for 72 hrs in vitro alone (B16-PBS#1; dark blue) or  with TNFD(B16-PBS#1+TNFD; green). 710 
B16 MRD cells recovered from the site of B16tk cell injection after regression were treated with 711 
TNFD for 72 hrs (B16 MRD + TNFD 72 hrs; purple).Cells from a small recurrent B16tk tumor 712 
(~0.3cm diameter) explanted following regression after GCV treatment was cultured for 72 713 
hours without TNFD (B16 REC#1; light blue).  Representative of three separate experiments.  B 714 
and C, MRD B16 cells expanded for 72hrs in TNFD,  parental B16 cells , explanted B16tk 715 
recurrent tumor cells,  or explanted primary B16 tumors were plated (104 cells per well).  24 716 
hours later, 105 purified NK cells from C57BL/6 mice were added to the wells with control IgG  717 
or anti-PD-L1.  48 hours later supernatants were assayed for B, IFNJ or C, IL6 by ELISA.  Mean 718 
of triplicates per treatment are shown.  Representative of three separate experiments (ANOVA).  719 
D,  cDNA from three explants of PBS-treated B16ova primary tumors (~0.3cm diameter) and 720 
three MRD B16ova cultures (derived from skin explants after regression with OT-I T-cell 721 
therapy and growth for 72hrs in TNFD) were screened by qrtPCR for expression the ova gene.  722 
Relative quantities of ova mRNA were determined (ANOVA). Statistical significance was set at 723 
p<0.05 for all experiments.  E,  104 parental B16ova cells; or F, MRD B16ova cells (derived as 724 
previously stated)were cocultured with purified CD8+ OT-I T cells and/or purified NK cells from 725 
either wildtype C57BL/6 or from IL6 KO mice (OT-I:NK:Tumor 10:1:1) in triplicate in the 726 
presence or absence of anti-IL6.  72 hours later, supernatants were assayed for IFNJ by ELISA.  727 
Mean and standard deviation of the triplicates are shown.  Representative of three separate 728 
experiments.  ** p<0.01 (ANOVA).   G, 104 B16ova MRD cells (derived as already 729 
described)were cultured in triplicates, as in F.  72 hours later, cells were harvested and analyzed 730 
for intracellular ,)1ȖH,  After 7 days of coculture, cDNA was screened by qrtPCR for 731 
expression of the ova gene. **p<0.01;  *** p<0.001 (ANOVA); Mean of each treatment is 732 
shown. 733 
Figure 6. Phenotyping of T cells.  Circulating lymphocytes from a tumor naïve C57BL/6 mice 734 
(left column) were compared to those from C57BL/6 mice treated and cleared of B16 primary 735 
tumors (right column) (n=2 mice per group, representative of  four independent experiments). 736 
Multiparametric flow cytometry for live A, CD4+
 
or CD8+ T cells; B and E, The fraction of 737 
CD4+ or CD8+ cells that are CD62Lhi or effector (CD62Llo CD44hi) phenotype. C and F, The 738 
fraction of CD62Lhi CD4+ or CD8+ cells expressing  the inhibitory receptors (IR) PD1 and TIM-739 
3. D and G,  The fraction of CD62Llo CD44hi effector cells expressing  the IRs PD1 and TIM-3. 740 
To analyze quantitative flow cytometry data, one-way ANOVA testing was conducted with a 741 
Tukey post-test, p values reported from these analyses were corrected to account for  multiple 742 
comaparisons. 743 
Figure 7.  Inhibition of tumor recurrence in vivo.  A,  5-day established subcutaneous B16tk 744 
tumors were treated with GCV i.p. on days 6-10 and 13-17.  On day 27, mice with no palpable 745 
tumors were treated with control IgG, anti-asialo GM-1 (NK depleting), anti-TNFD, or anti-PD1 746 
every other day for three weeks and survival was assessed.  Survival analysis was conducted 747 
using log-rank tests.  The threshold for significane was determined by using the Bonferroni 748 
correction for multiple comparisons.  Mice which developed a recurrent tumor were euthanized 749 
when the tumor reached a diameter of 1.0 cm.  Eight mice per group, except for the GCV/anti-750 
asialo GM-1 group n=9.  *p<0.01 Representative of two separate experiments.   B,  Triplicate 751 
cultures of 106 splenocytes and LN cells from C57BL/6 mice were incubated with PBS, LPS (25 752 
ng/ml), or CpG for 48 hours, and supernatants were assayed for TNFD by ELISA.  Mean and 753 
standard deviation of triplicates are shown; ***p<0.0001 PBS vs LPS (t test).  C,  Cumulative 754 
results from skin explants at the sites of tumor from tumor-regressed mice treated with GCV 755 
(B16tk tumors), reovirus therapy (B16tk cells), or OT-I adoptive T-cell therapy (B16ova cells).  756 
Explants were cocultured with 106 splenocytes and LN cells from C57BL/6 mice in the presence 757 
of PBS, LPS, CpG, or LPS plus anti-TNFD (0.4µg/ml).  7 days later,  adherent B16 tumor cells 758 
were counted and wells containing >104 cells were scored for active growth of MRD cells.   759 
P<0.001 LPS vs all other groups (ANOVA).  D,  5-day established subcutaneous B16tk were 760 
treated with GCV i.p. on days 6-10 and 13-17 On days 27 and 29, mice with no palpable tumors 761 
were treated with LPS (25µg/injection).Mice were treated in-parallel with control IgG, anti-762 
asialo GM-1, anti-TNFD, or anti-PD1 every other day for three weeks.  Mice with  recurrent 763 
tumors were euthanized when the tumors reached a diameter of 1.0 cm.  Survival of mice with 764 
time is shown.  **p<0.01;  *** p<0.001.  Survival analysis was conducted using log-rank tests.  765 
The threshold for significance was determined by using the Bonferroni correction for multiple 766 
comparisons.  Representative of two experiments.           767 
 768 
 769 
 770 
  
Culture Conditions    Rate of Outgrowth 
     >104 cells on d7 
  
Explant alone 2/19 
  
Explant + Control Spl/LN 0/7 
  
Explant + Tumor Rejected Spl/LN 4/6 
  
Explant + VEGF 0/4 
  
Explant + Control Spl/LN + VEGF 2/5 
  
Explant + Tumor Rejected Spl/LN + VEGF 4/4 
  
*  MRD explants from any of 4 different primary treatments. 
Table 1 
Table 2 











